RxDoctor Payments Data

Sameer Naranje

Orthopaedic Surgery · Birmingham, ALNPI 1891098851

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,021 of the $11,781 with a category attached, or 68.1%. 22 manufacturers reported payments, led by Smith+Nephew at 26.1% of the total. Reporting peaked in 2019 at $5,469 and has fallen 98.7% since, to $72 in 2025.

$11,781in general payments, 2019–2025

Across 132 payments — averaging $89.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$3K
  • Omnilife Science, Inc$2K
  • Zimmer Biomet$2K
  • Medacta USA, Inc.$1K
  • Johnson & Johnson$674
  • Corin USA$599
  • plus $2K from 16 others
$5,700in research payments, 2019–2025

Across 4 payments — averaging $1425.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotissue Holdings Inc.$6K

What the payments were for

  • Travel & lodging$3,76032%
  • Food & beverage$8,02168%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,781 in reported general payments places this provider in the 75th percentile of 319 orthopaedic surgery providers in Alabama.

See all orthopaedic surgery providers in Alabama →

Medicare billing

Part B allowed, 2024
$79,188
Medicare patients
122
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib11$327
Oxycodone Hcl58$310
Pregabalin11$173
Meloxicam45$170
Gabapentin23$125
Tramadol Hcl42$120
Methocarbamol14$87
Amoxicillin11$9

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Birmingham

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →